Merry Christmas and Happy New Year to all my pharma colleagues. May you have a healthy and prosperous new year to share with your family and friends.
Bob Bianchi’s interview with Joe Lavelle, host of Intrepid Now Healthcare, discussing the government response to the Opioid Crisis, was chosen as one of the Top 10 intrepidNOW Healthcare Interviews of 2017 as measured by the number of opens!
Click here for the full story.
The Opioid Crisis: Government Response
Bob joined Joe Lavelle, host of Intrepid Now Healthcare, to discuss our government response to the Opioid Crisis (which was just formally declared as a public health emergency by President Trump). This podcast was sponsored by National Medical Services Laboratories (NMS Labs) Willow Grove, PA. Specifically, we discuss the following with Bob:
1. We don’t have to look far into the current news to find that the opioid epidemic has reached a critical mass in the U.S., will you start by sharing some of the factors that have contributed to this growing problem?
2. Why do you think prescription drug abuse is such a rapidly growing problem?
3. Do you think we are doing enough to ensure the appropriate use of prescription drugs with high abuse potential?
4. How has the Federal government responded to this growing epidemic?
5. Will you talk a bit more about this FDA Action Plan?
6. What can and should the government be doing next to combat the opioid crisis?
Click here to hear the webinar.
The Opioid Crisis: Industry Response
Bob joined Joe Lavelle, host of Intrepid Now Healthcare, to discuss industry response to the Opioid Crisis (which was just formally declared as a public health emergency by President Trump). This podcast was sponsored by National Medical Services Laboratories (NMS Labs) Willow Grove, PA. Specifically, we discuss the following with Bob:
1. How have the pharmaceutical manufacturers responded to the opioid crisis?
2. How have the distributors and insurers/payers responded to the opioid crisis?
3. How will this situation continue to evolve over the next 5 years?
Click here to hear the webinar.
This message announces an informative invitro study webinar which will benefit all participants. I encourage all of you to attend the webinar and January meeting.
Category 1 in vitro abuse deterrence testing has grown into its own field of science.
It is not similar to other in vitro studies we perform in the pharmaceutical industry and it also involves different challenges, data and people than what is obtained from Category 2-4 abuse deterrent testing. Therefore, a focus group specifically addressing issues related to Category 1 testing was formed. We have had two successful meeting so far and the 3rd event is to take place in Jan 2018. The event is more relevant than ever as the FDA has made the Final Guidance to Industry for labeling and approval of generic ADF products, which will be an important topic for discussion.
During this webinar the audience will learn what can be considered “state of the art” and what can be relevant in the future for Category 1 tests – also in light of the new “Generic ADF Guideline”. The webinar will be a preparation for the 3rd Category One Focus Group meeting. Therefore, the webinar will be interactive with live chat, polls and questions. Topics of interest will be fed into the working group sessions during the meeting in January.
Participants of the webinar will receive a promotion code for the registration fee for the 3rd Category 1 Focus Group Meeting in January 2018.
After registering, you will receive a confirmation email containing information about joining the webinar.
We hope you join us for this pre-meeting webinar.
-Category 1 Focus Group Steering Committee
This email and any files transmitted with it are intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any review, transmission, re-transmission, dissemination or other use of, or taking of any action in reliance upon this information by persons or entities other than the intended recipient is prohibited. If you have received this email in error, please notify the sender by email or phone (800-235-4890), do not read the contents, delete and destroy this message and its attachments.